

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
12 May 2022 (12.05.2022)



(10) International Publication Number
WO 2022/096716 A3

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)

C07K 16/30 (2006.01)

(21) International Application Number:

PCT/EP2021/080956

(22) International Filing Date:

08 November 2021 (08.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/110,957 06 November 2020 (06.11.2020) US

63/231,877 11 August 2021 (11.08.2021) US

(71) Applicants: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **AMGEN RESEARCH (MUNICH) GMBH** [DE/DE]; Staffelsee 2, 81477 Munich (DE).

(72) Inventors: **EVERTS, Stephanie**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **KLINGER, Matthias**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **NAEGELE, Virginie**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **ZALEWSKI, Adam**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **BLUEMEL, Claudia**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **BOEHM, Thomas**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **BROZY, Johannes**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **D'ANGELO, Igor**; c/o Amgen Inc, One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **KUFER, Peter**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **LUTTERBUENSE, Petra**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **MUENZ, Markus**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **RAU, Doris**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **RAUM, Tobias**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **RATTEL, Benno**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **THOMAS, Oliver**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE).

ULLRICH, Ines; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **WAHL, Joachim**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **WEBHOFER, Christian**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE). **WEIDLER, Sascha**; c/o Amgen Research (Munich) GmbH, Staffelsee 2, 81477 Munich (DE).

(74) Agent: **WEINZIERL, Gerhard Dr.** et al.; c/o Schiweck Weinzierl Koch, Ganghoferstrasse 68b, 80339 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

11 August 2022 (11.08.2022)

(54) Title: MULTITARGETING BISPECIFIC ANTIGEN-BINDING MOLECULES OF INCREASED SELECTIVITY

(57) Abstract: The present invention provides multitargeting bispecific antigen-binding molecules characterized by comprising a first and a second bispecific entity each comprising a domain binding to target, a second domain binding to an extracellular epitope of the human and the *Macaca* CD3e chain, wherein both bispecific entities are linked to each other by a spacer which spaces apart the first and the second bispecific entity. Moreover, the invention provides a polynucleotide, encoding the multitargeting bispecific antigen-binding molecule, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.



WO 2022/096716 A3